Skip content
Porcine

Porcine

Porcine

Estrus Management

SwineMate® (altrenogest)

Product Image
Product Image
Product Image
Get Aurora

Estrus Management

SwineMate® (altrenogest)

Package Presentation

1000 mL Bottle

Reorder No: 22000

Get Aurora

Product
Features

  • Dosage – 6.8 mL/day for 14 consecutive days (15 mg of altrenogest per day)
  • Achieve standing heat 4-9 days after SwineMate® treatment
  • The cost-effective alternative to MATRIX®
  • The same active ingredient as MATRIX®
  • Contains altrenogest, the same active ingredient as MATRIX®
  • Predictable breeding time table for sexually mature gilts that have had at least one estrus
  • SwineMate® is used to synchronize the estrous cycle of gilts
  • Approved by FDA under ANADA 200-621
  • Manufactured under GMP standards for quality and consistency
  • MATRIX® is a Registered Trademark of Merck Animal Health

Indications

For synchronization of estrus in sexually mature gilts that have had at least one estrous cycle. Treatment with SwineMate® results in estrus (standing heat) 4 to 9 days after completion of the 14-day treatment period.

DIRECTIONS: Administer 6.8 mL (15 mg altrenogest) per gilt once daily for 14 consecutive days. Treat gilts on an individual animal basis by top-dressing SwineMate® on a portion of each gilt’s daily feed allowance. To produce the desired synchronization of estrus in a group of gilts, treat all of the gilts daily for the same 14-day period.

Safety
Info

IMPORTANT SAFETY INFORMATION:

SwineMate® is contraindicated for use in gilts having a previous or current history of uterine inflammation (i.e., acute, subacute or chronic endometritis). Underdosing of SwineMate® may lead to the occurrence of cystic follicles. Animals intended for human consumption must not be slaughtered within 21 days of the last treatment with this drug product. Avoid skin contact. SwineMate® is absorbed through unbroken skin, and exposure may result in serious side effects to both women and men. Always wear vinyl, neoprene, or nitrile protective gloves when handling SwineMate or when in contact with equipment or surfaces contaminated by this product. Latex gloves are not protective. PREGNANT WOMEN OR WOMEN WHO MAY BE PREGNANT SHOULD NOT HANDLE SWINEMATE®. WOMEN OF CHILDBEARING AGE SHOULD EXERCISE EXTREME CAUTION WHEN HANDLING THIS PRODUCT. SwineMate® is readily absorbed through the skin and could lead to a disruption of the menstrual cycle or prolongation of pregnancy. People who should not handle this product include women who are or may be pregnant, anyone with blood clots or clotting disorders, or with a history of these events, anyone with a history of heart disease or stroke, women with known or suspected breast cancer, people with known or suspected estrogen-dependent cancer, women with vaginal bleeding of unknown cause, people with tumors which developed during the use of oral contraceptives or other estrogen-containing products, anyone with liver dysfunction or disease. Accidental spillage on the skin should be washed off immediately with soap and water. Keep out of the reach of children. For complete safety information, refer to the product label.

Safety
Info

IMPORTANT SAFETY INFORMATION:

SwineMate® is contraindicated for use in gilts having a previous or current history of uterine inflammation (i.e., acute, subacute or chronic endometritis). Underdosing of SwineMate® may lead to the occurrence of cystic follicles. Animals intended for human consumption must not be slaughtered within 21 days of the last treatment with this drug product. Avoid skin contact. SwineMate® is absorbed through unbroken skin, and exposure may result in serious side effects to both women and men. Always wear vinyl, neoprene, or nitrile protective gloves when handling SwineMate or when in contact with equipment or surfaces contaminated by this product. Latex gloves are not protective. PREGNANT WOMEN OR WOMEN WHO MAY BE PREGNANT SHOULD NOT HANDLE SWINEMATE®. WOMEN OF CHILDBEARING AGE SHOULD EXERCISE EXTREME CAUTION WHEN HANDLING THIS PRODUCT. SwineMate® is readily absorbed through the skin and could lead to a disruption of the menstrual cycle or prolongation of pregnancy. People who should not handle this product include women who are or may be pregnant, anyone with blood clots or clotting disorders, or with a history of these events, anyone with a history of heart disease or stroke, women with known or suspected breast cancer, people with known or suspected estrogen-dependent cancer, women with vaginal bleeding of unknown cause, people with tumors which developed during the use of oral contraceptives or other estrogen-containing products, anyone with liver dysfunction or disease. Accidental spillage on the skin should be washed off immediately with soap and water. Keep out of the reach of children. For complete safety information, refer to the product label.

Cookies & Privacy

Our website uses cookies. By using our website and agreeing to this policy, you consent to our use of cookies in accordance with our Privacy Policy and our Terms and Conditions.